CAS Registry Number raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-25. Anything still debated is marked as such rather than presented as settled.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
== Function and application == Due to the desirable properties of peptides such as high receptor affinity and bioactivity, and low toxicity, the use of peptides in therapeutics (i. e. as peptide therapeutics) has great potential; shown by a fast growing market with over 100 approved peptide-based drugs. The disadvantages are that peptides have low oral bioavailability and stability. Lipidation as a chemical modification tool in the development of therapeutic agents has proven to be useful in overcoming these issues, with four lipidized peptide drugs currently approved for use in humans, and various others in clinical trials. Two of the approved drugs are long-acting anti-diabetic GLP-1 analogues liraglutide (Victoza®), and insulin detemir (Levemir®). The other two are the antibiotics daptomycin and polymyxin B. Lipidated peptides also have applications in other areas, such as use in the cosmetic industry. A commercially available lipidated peptide, Matrixyl, is used in anti-wrinkle creams. Matrixyl is a pentapeptide and has the sequence KTTKS, with an attached palmitoyl lipid chain, that is able to stimulate collagen and fibronectin production in fibroblasts. Several studies have shown promising results of palmitoyl-KTTKS, and topical formulations have been found to significantly reduce fine lines and wrinkles, helping to delay the aging process in the skin.
=== 1971–1972: Islands === After a search for a drummer to replace McCulloch, Ian Wallace was secured. Fripp was re-energised by the addition of a new member, and he joined Collins and Wallace to audition singers and bassists. Singers who tried out included Bryan Ferry of Roxy Music (Sinfield would produce Roxy Music's first album in 1972) and even one of the band's managers, John Gaydon. The position eventually went to Raymond "Boz" Burrell. John Wetton was invited to join on bass, but declined in order to join Family instead. Rick Kemp (later of Steeleye Span) rehearsed with the band, but declined the final offer to formally join. Fripp decided to teach Burrell to play bass rather than continue the labored auditions. Though he had not played bass before, Burrell had played enough acoustic guitar to assist him in learning the instrument quickly. Wallace was able to further instruct Burrell in functioning on the instrument in a rhythm section.With a line-up now complete, King Crimson began touring in May 1971, the first time they had played live since the original line-up's last show on 14 December 1969. The concerts were well received, but musical differences and the somewhat wilder lifestyles of Collins, Wallace, and Burrell alienated the non-drug-taking Fripp, who began to withdraw socially from his bandmates, creating further tension. In 1971, the new King Crimson formation recorded Islands.
In 2021, the average annual salary in the private sector was €18,630 for women and €24,640 for men, reflecting a 24.4% gap. This difference is partially attributed to variations in working hours, job types, and the prevalence of part-time work, which accounted for approximately 40% of the wage gap in 2017. When adjusted to full-time equivalents, the average wage gap was 15.5% in 2021, down from 17.5% in 2016. The wage gap tends to increase with age: it was 4.6% at age 25 and rose to 27.5% among those over 60. Differences in working time decrease with age, from 20% under age 25 to 10% between ages 25 and 60. For workers, women earned 14.3% less than men for equivalent hours and worked 23.3% fewer hours. Among employees, women earned 4.7% less for similar hours and had nearly equal working time. The pay gap for equal hours was 16.1% among executives and 12.2% among intermediate professions, with women in these groups also working fewer hours (4.7% and 10.9%, respectively). For equivalent positions and working hours, the wage gap was 4.3%, though occupational segregation—such as differences in sector and employer—affects this figure. In the public sector, the overall gender wage gap was 14%. Among executives, the gap was 23%; among workers, 17%; and among employees, 7%. For full-time salaried positions, the gender wage gap declined from 29.4% in 1976 to 16.3% in 2017. The gap narrowed steadily until 1980, remained largely stable until 2000, and began to decrease again thereafter, though part-time employment among women influenced this trend.
In January 2023, Vice President Geraldo Alckmin met with Vice President Frans Timmermans of the EU Commission in Brasília. During his visit to Brazil, Timmermans said that President Lula's efforts to end destruction in the Amazon deserves support and cooperation from the European Union, adding that the EU could donate up to €750,000 to help the Yanomami people facing a humanitarian crisis. In March 2023, the EU's commissioner for competition Margrethe Vestager met with Vice President Alckmin and other Brazilian officials during a meeting in Brasília to unveil the EU-Brazil bilateral Investment Map. In June 2023, Lula met with EU president Ursula von der Leyen to discuss areas such as environment, science and technology and trade, namely the EU-Mercosur trade deal. Lula expressed concerns over a European Union's side letter proposal of sanctioning Mercosur goods in case they fail to meet environmental goals saying that "between partners there should be mutual confidence not mistrust and sanctions" and that the sanctions could hurt genuine Brazilian green efforts. During the meeting the European Union pledged to donate 20 million euros to the Amazon Fund. In July 2023, numerous Latin American, Caribbean and European leaders, including Lula, attended the III EU-CELAC summit in Brussels to discuss topics such as global hunger, inequalities, poverty and climate change. On the sidelines of the summit, Lula made the case for the EU-Mercosur trade deal and expressed concern for protectionist policies in the agreement.
Cyclofenil, sold under the brand name Sexovid among others, is a selective estrogen receptor modulator (SERM) medication which is used as a gonadotropin stimulant or ovulation inducer and in menopausal hormone therapy in women. It is mostly no longer available. The medication is taken by mouth. Side effects of cyclofenil include liver toxicity among others. It is a selective estrogen receptor modulator (SERM) and hence is a mixed agonist–antagonist of the estrogen receptor (ER), the biological target of estrogens like estradiol. It has antiestrogenic effects on the hypothalamic–pituitary–gonadal axis and hence can increase sex hormone production and stimulate ovulation. Cyclofenil was introduced for medical use in 1970. It has been mostly discontinued, but remains available in a few countries, including Brazil, Italy, and Japan. It has been used as a doping agent by male athletes.
Sources: en.wikipedia.org
=== Pre-discovery use === The use of pitchblende, uranium in its natural oxide form, dates back to at least the year 79 AD, when it was used in the Roman Empire to add a yellow color to ceramic glazes. Yellow glass with 1% uranium oxide was found in a Roman villa on Cape Posillipo in the Gulf of Naples, Italy, by R. T. Gunther of the University of Oxford in 1912. Starting in the late Middle Ages, pitchblende was extracted from the Habsburg silver mines in Joachimsthal, Bohemia (now Jáchymov in the Czech Republic) in the Ore Mountains, and was used as a coloring agent in the local glassmaking industry. In the early 19th century, the world's only known sources of uranium ore were these mines.
The five other countries, including the second and third largest beef producers, France and the United Kingdom, respectively, permitted their use. This had resulted in disputes, with countries that had no prohibitions arguing that the restrictions by the others acted as non-tariff trade barriers. In response to the public outcry, in combination with the discovery that DES was a teratogen, in 1980 the EU began to issue regulations, beginning with prohibiting the use of stilbenes and thyrostatics by the European Community Council of Agriculture Ministers in 1980, and commissioning of a scientific study into the use of estradiol, testosterone, progesterone, trenbolone, and zeranol in 1981. The European Consumers' Organisation (BEUC) lobbied for a total ban upon growth hormones, opposed, with partial success, by the pharmaceutical industry. (In 1987 the European Federation of Animal Health (FEDESA), formed to represent, amongst other things, companies that manufactured growth hormones.) Neither European farmers nor the meat processing industry took a stance on the matter. With the help of the BEUC consumer boycotts of veal products, sparked by the Italian scandals and similar reports in France and Germany, spread across the EU, causing companies such as Hipp and Alete to withdraw their veal products, while veal prices dropped in France, Belgium, West Germany, Ireland, and the Netherlands. Because of the fixed purchases guaranteed by the EU's Common Agricultural Policy, ECU 10 million came out of the EU budget.
== Exhibitions == 1933, 10–30 June, Vision féériques d’Orient (Fantasy Perspectives of the East), Paris, town hall of 13th district 1956, 26 May – June, Festival d’architecture et d’art monumental (Monument Architecture and Art Festival), Grand Palais, Paris. Exhibition of some originals from La Basilique de Sainte Sophie (Αγία Σοφία) de Constantinople (The Basilica of Hagia Sophia of Constantinople). 1999, 2 September – 9 October, Yapı Kredi Cultural Centre, exhibition space of the Sermet Çifter Library, İstiklál Cad. 285, Beyoğlu, Turkey. Exhibition of originals from L’Art Islamique en Orient 1, 2 et 3 (Islamic Art in the East 1, 2 and 3). 2021–2022, Exhibition at the Péra Museum – November 2021 – March 2022 – of several of his originals concerning Ayia-Sophia, Theodora and Constantinople (Istanbul).
Papanicolaou staining, or PAP staining, was developed to replace fine needle aspiration cytology (FNAC) in hopes of decreasing staining times and cost without compromising quality. This stain is a frequently used method for examining cell samples from a variety of tissue types in various organs. PAP staining has endured several modifications in order to become a “suitable alternative” for FNAC. This transition stemmed from the appreciation of wet fixed smears by scientists preserving the structures of the nuclei opposed to the opaque appearance of air dried Romanowsky smears. This led to the creation of a hybrid stain of wet fixed and air dried known as the ultrafast papanicolaou stain. This modification includes the use of nasal saline to rehydrate cells to increase cell transparency and is paired with the use of alcoholic formalin to enhance colors of the nuclei. The papanicolaou stain is now used in place of cytological staining in all organ types due to its increase in morphological quality, decreased staining time, and decreased cost. It is frequently used to stain Pap smear specimens. It uses a combination of haematoxylin, Orange G, eosin Y, Light Green SF yellowish, and sometimes Bismarck Brown Y.
Vinylene carbonate (VC) or 1,3-dioxol-2-one, is the simplest unsaturated cyclic carbonic acid ester. Vinylene carbonate can also be thought of as the cyclic carbonate of the hypothetical (Z)-ethene-1,2-diol. The activated double bond in this five-membered oxygen-containing heterocycle makes the molecule a reactive monomer for homopolymerization and copolymerization and a dienophile in Diels-Alder reactions. Below room temperature vinylene carbonate is a colorless stable solid.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.